Kalos Therapeutics Overview
- Year Founded
-
2005

- Status
-
Private
- Employees
-
2

- Latest Deal Type
-
2ndary - Private
Kalos Therapeutics General Information
Description
Developer of atrial natriuretic peptides designed to help in the treatment of cancer in patients. The company's peptides develop a safe nontoxic therapeutic that has the potential to inhibit the growth of rapidly dividing human cancer cells and put them into a sustained non-dividing state, enabling patients to receive a new class of drugs to treat cancer.
Contact Information
Website
www.kalostherapeutics.comCorporate Office
- 2550 West Union Hills Drive
- Suite 350
- Phoenix, AZ 85027
- United States
Corporate Office
- 2550 West Union Hills Drive
- Suite 350
- Phoenix, AZ 85027
- United States
Kalos Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Secondary Transaction - Private | 01-May-2024 | Completed | Generating Revenue | |||
2. Later Stage VC (Series B) | 01-May-2016 | Completed | Generating Revenue | |||
1. Later Stage VC (Series A) | 01-Nov-2015 | $1.27M | $1.27M | Completed | Generating Revenue |
Kalos Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | ||||||||
Series A |
Kalos Therapeutics Patents
Kalos Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-2853204-A1 | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases | Inactive | 16-Dec-2011 | ||
EP-2790714-A2 | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases | Inactive | 16-Dec-2011 | ||
JP-2018024674-A | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases | Pending | 16-Dec-2011 | ||
US-20150045301-A1 | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases | Inactive | 16-Dec-2011 | ||
EP-2790714-A4 | Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases | Inactive | 16-Dec-2011 | A61K38/2242 |
Kalos Therapeutics Signals
Kalos Therapeutics FAQs
-
When was Kalos Therapeutics founded?
Kalos Therapeutics was founded in 2005.
-
Where is Kalos Therapeutics headquartered?
Kalos Therapeutics is headquartered in Phoenix, AZ.
-
What is the size of Kalos Therapeutics?
Kalos Therapeutics has 2 total employees.
-
What industry is Kalos Therapeutics in?
Kalos Therapeutics’s primary industry is Biotechnology.
-
Is Kalos Therapeutics a private or public company?
Kalos Therapeutics is a Private company.
-
What is Kalos Therapeutics’s current revenue?
The current revenue for Kalos Therapeutics is
. -
How much funding has Kalos Therapeutics raised over time?
Kalos Therapeutics has raised $1.62M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »